bioRxiv2018
Ebolavirus is a pathogen capable of causing highly lethal haemorrhagic fever in humans. The envelope-displayed viral glycoprotein is the primary target of humoral immunity induced by both natural exposure and vaccination. The epitopes targeted by B cells have been thoroughly characterised by functional and structural analyses of the glycoprotein, GP, yet there is a paucity of information regarding the cellular immune response to Ebolavirus. To date, no T cell epitopes in the glycoprotein have been characterised in detail in humans.\n\nA recent Phase I clinical trial of a heterologous prime-boost vaccination regime with viral vectors encoding filovirus antigens elicited strong humoral and T cell responses in vaccinees. Using samples from this trial, the most frequently recognised peptide pools were studied in more detail to identify the minimal epitopes recognised by antigen-specific T cells and associated HLA-restrictions.\n\nUsing IFN{gamma} ELISPOT and flow cytometry, we characterised nine highly immunogenic T cell epitopes located on both the GP1 and GP2 subunits of the Ebolavirus GP. Epitope mapping revealed the location of these epitopes as presented on the mature virion. HLA-typing on all participants, combined with in silico epitope analysis, determined the likely MHC class I restriction elements. Thirteen HLA-A and -B alleles were predicted to present the identified epitopes, suggesting promiscuous recognition and induction of a broad immune response.\n\nThe glycoprotein of Ebolavirus is highly immunogenic, inducing both CD4+ and CD8+ T cell responses and we have shown here for the first time that these responses are associated with multiple HLA types. Delivery of this antigen using a heterologous prime-boost approach with ChAd3 and MVA is likely to be highly immunogenic in genetically diverse human populations, due to the induction of responses against multiple immunodominant epitopes.\n\nAuthor SummaryThe West African Ebolavirus epidemic in 2013-2016 claimed more than 11,000 lives, eclipsing all previously recorded outbreaks combined. Understanding the mechanisms of host-pathogen interactions informs rational vaccine design. B cell epitopes have been described extensively through the characterisation of monoclonal antibodies from survivors of Ebolavirus disease. Despite a clear role for cellular immunity in survival of Ebolavirus disease, data relating to minimal T cell epitopes in the glycoprotein has so far only been obtained in murine. This study describes the first identification of human T cell epitopes in the surface glycoprotein of the Ebolavirus. These epitopes have been identified using samples from a clinical trial of viral vectored vaccines against the Zaire Ebolavirus undertaken during the 2013-2016 West African outbreak. We also describe the recognition of these epitopes through multiple HLA alleles. As efforts to progress a vaccine against Ebola towards licensure proceed, detailed characterisation of immunity to the virus contribute to our understanding of the potential application of vaccines in diverse populations.